루닛

328130KOSDAQ소프트웨어 개발 및 공급업

44.9 / 100

Reference Date: 2026-06-10

Financial Score7.5 / 40

News Sentiment20.4 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: ROE is below the industry average, PBR raises overvaluation concerns. Plunged 29.8% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Lunit is a deep learning-based medical AI company specializing in cancer diagnosis and breast cancer screening solutions, leveraging AI-assisted detection and imaging biomarker technologies. Its core products, Lunit INSIGHT and Lunit SCOPE, drive innovation in the medical AI market, with 92% of revenue generated from overseas markets, including the U.S. and Japan.

Number of Employees

272people

Average Salary

93.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 13.624.0Point

PBR

7.92Industry Average 1.020.0Point

7.8x industry avg (risky)

ROE

-31.58Industry Average 1.100.0Point

Well below industry avg

Debt Ratio

14.75Industry Average 7.930.5Point

1.9x industry avg (risky)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲84.7% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼41.5% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -32.3% (declining, 3yr)

Detailed News Sentiment

19 totalPositive 17Neutral 1Negative 1Average Sentiment Score 81.6

Positive
루닛, 엔비디아 주최 간담회 참석…“AI 의료 글로벌 협력 모색”
루닛이 엔비디아 CEO와의 만남을 통해 글로벌 의료 AI 협력 강화를 모색하며 긍정적인 시장 반응을 기대.
Positive
"엔비디아가 불렀다"…루닛, 젠슨 황과 의료 AI 협력 논의
루닛이 엔비디아와의 협력 논의 참여로 의료 AI 분야에서의 혁신 가능성이 높아져 긍정적인 전망을 받고 있다.
Positive
"판독 편차 줄인다"…루닛-라이카, 폐암 바이오마커 AI 솔루션
루닛의 AI 기반 폐암 바이오마커 분석 기술이 진단 정확도와 효율성을 향상시켜 시장 경쟁력을 강화했다.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 14,630Won52-week high 53,93452-week low 14,630

1-month return0.0Point

1m -29.83% (strong drop)

Volume trend6.0Point

Volume increasing

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral전환사채(해외전환사채포함)발행후만기전사채취득 (제2회차)2026-06-01
Neutral[기재정정]전환사채(해외전환사채포함)발행후만기전사채취득 (제1회차)2026-06-01
Neutral지속가능경영보고서등관련사항(자율공시)2026-05-29
Neutral분기보고서 (2026.03)2026-05-12